An international multisite research collaboration, including CITF-funded researcher Dr. Andrés Finzi from the Université de Montréal, used genetically modified mice that mimic COVID-19 disease in humans to study how antibodies from people who have recovered from COVID-19 could prevent severe disease in other people.
CITF-funded researcher Dr. Pascal Lavoie from the University of British Columbia and his collaborators are suggesting that the presence of antibodies to SARS-CoV-2 may not necessarily indicate a previous infection. Using highly sensitive tests, they discovered pre-existing antibodies to SARS-CoV-2 in many uninfected adults. The study was funded in part by the COVID-19 Immunity [...]
Dr. Ishac Nazy and the McMaster Platelet Immunology Laboratory have found some of the reasons behind why some patients with severe COVID-19 have blood clots.
Dr. Andrés Finzi from the Université de Montréal and Dr. Renée Bazin from Héma-Québec and their teams recently describe a novel high-throughput method to track levels of antibodies made against SARS-CoV-2 spike protein in the plasma of donors that recovered from COVID-19 in a recent issue of Transfusion.
Dr. Andrés Finzi, from the Université de Montréal, Dr. Renée Bazin from Héma-Québec, along with collaborators from Western University, are highlighting the importance of antibodies made early on in the infection in SARS-CoV-2 neutralization.
Researchers from Université de Montréal, Dr Daniel Kaufmann and Dr Andres Finzi, in collaboration with researchers from New York University, are confirming the presence of a long-lasting immune response to the novel coronavirus SARS-CoV-2, in a pre-print publication.
Researchers at the University of Toronto, published in the Journal of Immunology, shed light on what is happening in the body may help to explain why patients with SARS-CoV-2 have more severe inflammation and lung tissue damage than patients suffering from regular seasonal influenza virus.
A group of Canadian researchers, led by Andrés Finzi from the Université de Montréal, investigated the duration of antibodies against SARS-CoV-2 in people who were recovering from COVID-19.
Researchers from Université de Montréal and Héma Québec, led by Dr. Andrés Finzi and Dr. Renée Bazin, and working with collaborators across Canada, are reporting that antibodies against SARS-CoV-2 Spike correlate with COVID-19 severity.